Insmed (INSM) Current Assets (2010 - 2026)
Insmed (INSM) posted quarterly Current Assets of $1.6 billion for Q1 2026, up 15.01% year-over-year from $1.4 billion in Q1 2025, and down 10.09% quarter-over-quarter from $1.8 billion in Q4 2025.
Insmed (INSM) Current Assets (2010 - 2026) Analysis & Trends
Insmed's Current Assets history runs 17 years deep, the most recent figure standing at $1.6 billion for Q1 2026.
- In Q1 2026, Current Assets rose 15.01% year-over-year to $1.6 billion; the TTM figure through Mar 2026 stood at $1.6 billion (up 15.01% YoY), while the FY2025 annual figure was $1.8 billion, up 10.64% from the prior year.
- Current Assets for Q1 2026 stood at $1.6 billion, down from $1.8 billion in the prior quarter.
- The five-year high for Current Assets was $2.1 billion in Q2 2025, with the low at $632.2 million in Q3 2022.
- The 5-year median for Current Assets is $1.3 billion (2022), against an average of $1.3 billion.
- The sharpest annual moves came in 2022 and 2025: Current Assets sank 35.01% in 2022, then jumped 84.88% in 2025.
- Insmed's Current Assets stood at $1.3 billion in 2022, then slipped by 27.04% to $929.1 million in 2023, then soared by 74.55% to $1.6 billion in 2024, then advanced by 10.64% to $1.8 billion in 2025, then declined by 10.09% to $1.6 billion in 2026.
- Business Quant data shows INSM's Current Assets at $1.6 billion in Q1 2026, $1.8 billion in Q4 2025, and $1.9 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 4.74 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.63 Bn |
| Mar 31, 2026 | 1.61 Bn |
| Dec 31, 2025 | 1.79 Bn |
| Sep 30, 2025 | 1.93 Bn |
| Jun 30, 2025 | 2.08 Bn |
| Mar 31, 2025 | 1.40 Bn |
| Dec 31, 2024 | 1.62 Bn |
| Sep 30, 2024 | 1.65 Bn |
| Jun 30, 2024 | 1.42 Bn |
| Mar 31, 2024 | 758.72 Mn |
| Dec 31, 2023 | 929.06 Mn |
| Sep 30, 2023 | 926.58 Mn |
| Jun 30, 2023 | 1.05 Bn |
| Mar 31, 2023 | 1.13 Bn |
| Dec 31, 2022 | 1.27 Bn |
| Sep 30, 2022 | 632.17 Mn |
| Jun 30, 2022 | 674.73 Mn |
| Mar 31, 2022 | 756.14 Mn |
| Dec 31, 2021 | 837.04 Mn |
| Sep 30, 2021 | 958.98 Mn |